People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

the company's decision to construct new manufacturing sites in the U.S., creating thousands of jobs, indicates an aggressive expansion strategy. Such advances likely contributed to Eli Lilly's ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Findings from the Phase 3 BRAVE-AA-PEDS study were presented in a late ... Annual Meeting taking place March New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS achieved deep and ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced it has secured $65 million in ...

An estimated 6 to 17 percent of children have sleep-disordered breathing, ranging from snoring to sleep apnea, which can cause behavioral, neurocognitive, cardiovascular, and cardiometabolic issues. A ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...